source
- Angitia halts Phase 3 trial of AGA111 for degenerative disc diseaseAngitia Biopharmaceuticals announced that it has ended the Phase 3 study of its investigational therapy AGA111 in patients with degenerative disc disease who had undergone lumbar interbody fusion.…
- Biotech Scorecard Q3 Highlights Upcoming Trial Readouts from Amylyx and BiogenSTAT’s quarterly biotech scorecard lists fifteen events that could move biotech stocks, focusing on trial readouts and other milestones. Amylyx Pharmaceuticals reported results from its Phase 3 LU…